These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 8709110)

  • 1. Bis tertiary amide inhibitors of the HIV-1 protease generated via protein structure-based iterative design.
    Melnick M; Reich SH; Lewis KK; Mitchell LJ; Nguyen D; Trippe AJ; Dawson H; Davies JF; Appelt K; Wu BW; Musick L; Gehlhaar DK; Webber S; Shetty B; Kosa M; Kahil D; Andrada D
    J Med Chem; 1996 Jul; 39(14):2795-811. PubMed ID: 8709110
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structure-based design and synthesis of substituted 2-butanols as nonpeptidic inhibitors of HIV protease: secondary amide series.
    Reich SH; Melnick M; Pino MJ; Fuhry MA; Trippe AJ; Appelt K; Davies JF; Wu BW; Musick L
    J Med Chem; 1996 Jul; 39(14):2781-94. PubMed ID: 8709109
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potent human immunodeficiency virus type 1 protease inhibitors that utilize noncoded D-amino acids as P2/P3 ligands.
    Jungheim LN; Shepherd TA; Baxter AJ; Burgess J; Hatch SD; Lubbehusen P; Wiskerchen M; Muesing MA
    J Med Chem; 1996 Jan; 39(1):96-108. PubMed ID: 8568831
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Viracept (nelfinavir mesylate, AG1343): a potent, orally bioavailable inhibitor of HIV-1 protease.
    Kaldor SW; Kalish VJ; Davies JF; Shetty BV; Fritz JE; Appelt K; Burgess JA; Campanale KM; Chirgadze NY; Clawson DK; Dressman BA; Hatch SD; Khalil DA; Kosa MB; Lubbehusen PP; Muesing MA; Patick AK; Reich SH; Su KS; Tatlock JH
    J Med Chem; 1997 Nov; 40(24):3979-85. PubMed ID: 9397180
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A new structural theme in C2-symmetric HIV-1 protease inhibitors: ortho-substituted P1/P1' side chains.
    Wannberg J; Sabnis YA; Vrang L; Samuelsson B; Karlén A; Hallberg A; Larhed M
    Bioorg Med Chem; 2006 Aug; 14(15):5303-15. PubMed ID: 16621572
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structure-based design of novel HIV protease inhibitors: sulfonamide-containing 4-hydroxycoumarins and 4-hydroxy-2-pyrones as potent non-peptidic inhibitors.
    Thaisrivongs S; Janakiraman MN; Chong KT; Tomich PK; Dolak LA; Turner SR; Strohbach JW; Lynn JC; Horng MM; Hinshaw RR; Watenpaugh KD
    J Med Chem; 1996 Jun; 39(12):2400-10. PubMed ID: 8691434
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structure-based design: synthesis and biological evaluation of a series of novel cycloamide-derived HIV-1 protease inhibitors.
    Ghosh AK; Swanson LM; Cho H; Leshchenko S; Hussain KA; Kay S; Walters DE; Koh Y; Mitsuya H
    J Med Chem; 2005 May; 48(10):3576-85. PubMed ID: 15887965
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aza-peptide analogs as potent human immunodeficiency virus type-1 protease inhibitors with oral bioavailability.
    Fässler A; Bold G; Capraro HG; Cozens R; Mestan J; Poncioni B; Rösel J; Tintelnot-Blomley M; Lang M
    J Med Chem; 1996 Aug; 39(16):3203-16. PubMed ID: 8759643
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HIV-1 protease inhibitors with a transition-state mimic comprising a tertiary alcohol: improved antiviral activity in cells.
    Mahalingam AK; Axelsson L; Ekegren JK; Wannberg J; Kihlström J; Unge T; Wallberg H; Samuelsson B; Larhed M; Hallberg A
    J Med Chem; 2010 Jan; 53(2):607-15. PubMed ID: 19961222
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nonpeptidal P2 ligands for HIV protease inhibitors: structure-based design, synthesis, and biological evaluation.
    Ghosh AK; Kincaid JF; Walters DE; Chen Y; Chaudhuri NC; Thompson WJ; Culberson C; Fitzgerald PM; Lee HY; McKee SP; Munson PM; Duong TT; Darke PL; Zugay JA; Schleif WA; Axel MG; Lin J; Huff JR
    J Med Chem; 1996 Aug; 39(17):3278-90. PubMed ID: 8765511
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structure-activity relationships of novel HIV-1 protease inhibitors containing the 3-amino-2-chlorobenzoyl-allophenylnorstatine structure.
    Mimoto T; Nojima S; Terashima K; Takaku H; Shintani M; Hayashi H
    Bioorg Med Chem; 2008 Feb; 16(3):1299-308. PubMed ID: 17981045
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structure-based design of nonpeptidic HIV protease inhibitors: the sulfonamide-substituted cyclooctylpyramones.
    Skulnick HI; Johnson PD; Aristoff PA; Morris JK; Lovasz KD; Howe WJ; Watenpaugh KD; Janakiraman MN; Anderson DJ; Reischer RJ; Schwartz TM; Banitt LS; Tomich PK; Lynn JC; Horng MM; Chong KT; Hinshaw RR; Dolak LA; Seest EP; Schwende FJ; Rush BD; Howard GM; Toth LN; Wilkinson KR; Romines KR
    J Med Chem; 1997 Mar; 40(7):1149-64. PubMed ID: 9089336
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potent HIV protease inhibitors containing a novel (hydroxyethyl)amide isostere.
    Beaulieu PL; Wernic D; Abraham A; Anderson PC; Bogri T; Bousquet Y; Croteau G; Guse I; Lamarre D; Liard F; Paris W; Thibeault D; Pav S; Tong L
    J Med Chem; 1997 Jul; 40(14):2164-76. PubMed ID: 9216835
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stereospecific synthesis, structure-activity relationship, and oral bioavailability of tetrahydropyrimidin-2-one HIV protease inhibitors.
    De Lucca GV; Liang J; De Lucca I
    J Med Chem; 1999 Jan; 42(1):135-52. PubMed ID: 9888839
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potent and selective inhibitors of human immunodeficiency virus protease structurally related to L-694,746.
    Franchetti P; Perlini P; Abu Sheikha G; Cappellacci L; Grifantini M; Loi AG; De Montis A; Pani A; Marongiu ME; La Colla P
    Antivir Chem Chemother; 1998 Jul; 9(4):303-9. PubMed ID: 9875409
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cyclic urea amides: HIV-1 protease inhibitors with low nanomolar potency against both wild type and protease inhibitor resistant mutants of HIV.
    Jadhav PK; Ala P; Woerner FJ; Chang CH; Garber SS; Anton ED; Bacheler LT
    J Med Chem; 1997 Jan; 40(2):181-91. PubMed ID: 9003516
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design and synthesis of potent HIV-1 protease inhibitors incorporating hydroxyprolinamides as novel P2 ligands.
    Gao BL; Zhang CM; Yin YZ; Tang LQ; Liu ZP
    Bioorg Med Chem Lett; 2011 Jun; 21(12):3730-3. PubMed ID: 21555220
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design and synthesis of new potent C2-symmetric HIV-1 protease inhibitors. Use of L-mannaric acid as a peptidomimetic scaffold.
    Alterman M; Björsne M; Mühlman A; Classon B; Kvarnström I; Danielson H; Markgren PO; Nillroth U; Unge T; Hallberg A; Samuelsson B
    J Med Chem; 1998 Sep; 41(20):3782-92. PubMed ID: 9748353
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improved P1/P1' substituents for cyclic urea based HIV-1 protease inhibitors: synthesis, structure-activity relationship, and X-ray crystal structure analysis.
    Nugiel DA; Jacobs K; Cornelius L; Chang CH; Jadhav PK; Holler ER; Klabe RM; Bacheler LT; Cordova B; Garber S; Reid C; Logue KA; Gorey-Feret LJ; Lam GN; Erickson-Viitanen S; Seitz SP
    J Med Chem; 1997 May; 40(10):1465-74. PubMed ID: 9154969
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nonpeptide cyclic cyanoguanidines as HIV-1 protease inhibitors: synthesis, structure-activity relationships, and X-ray crystal structure studies.
    Jadhav PK; Woerner FJ; Lam PY; Hodge CN; Eyermann CJ; Man HW; Daneker WF; Bacheler LT; Rayner MM; Meek JL; Erickson-Viitanen S; Jackson DA; Calabrese JC; Schadt M; Chang CH
    J Med Chem; 1998 Apr; 41(9):1446-55. PubMed ID: 9554878
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.